Charcot-Marie-Tooth (CMT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Charcot-Marie-Tooth
disease (CMT) is a group of disorders marked by nerve demyelination or axon
degeneration, resulting in symptoms like muscle weakness, foot deformities,
chronic pain, and impaired balance. These symptoms typically manifest after age
5, significantly impacting physical and emotional well-being. CMT arises from
various gene mutations, with PMP22 gene mutations in 70-80% of CMT1 cases,
often due to genetic duplications on chromosome 17. MPZ gene mutations account
for 10-12% of CMT1 cases, with occasional involvement in other forms. CMT2 is
mainly linked to MFN2 gene mutations (about 20% of cases), while CMTX primarily
results from GJB1 gene mutations. Numerous other genes have also been
identified in smaller subsets of individuals with CMT, expanding our
understanding of the condition. Charcot-Marie-Tooth disease encompasses
multiple types classified by their impact on nerve cells and inheritance
patterns. CMT1 involves myelin abnormalities that slow nerve impulse
transmission, while CMT2 affects axons, weakening nerve impulses and
potentially leading to conditions like ALS. Intermediate types exhibit myelin
and axon abnormalities, while CMT4 stands out due to its distinctive
inheritance pattern. CMTX is linked to genes on the X chromosome and has
various subtypes denoted by letters and numbers. Currently, no cure is
available for Charcot-Marie-Tooth disease; it is not fatal, and most
individuals live an everyday life with active lifestyles. Sometimes, it may
affect the muscles needed for breathing, necessitating nighttime breathing
assistance. Common complications include falls, drug-related worsening of the
disease, and unnoticed foot injuries or infections due to decreased pain and
temperature sensation.
·
Charcot-Marie-Tooth disease affects 2.6
million people worldwide.
Thelansis’s
“Charcot-Marie-Tooth (CMT) Market Outlook, Epidemiology, Competitive Landscape,
and Market Forecast Report – 2023 To 2033" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential Charcot-Marie-Tooth
(CMT) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
KOLs insights of Charcot-Marie-Tooth
(CMT) across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Charcot-Marie-Tooth
(CMT) Market Forecast Patient Based Forecast Model (MS. Excel Based
Automated Dashboard), which Data Inputs with sourcing, Market Event, and
Product Event, Country specific Forecast Model, Market uptake and patient share
uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing
scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Tags: Charcot-Marie-Tooth
(CMT), Charcot-Marie-Tooth (CMT) market outlook, Charcot-Marie-Tooth
(CMT) competitive landscape, Charcot-Marie-Tooth
(CMT) market forecast, Thelansis, Primary market
research, KOL insights, Competitive Intelligence (CI)
Comments
Post a Comment